Stimulating the growth of blood vessels in the brain through the use of fibroblast growth factor 1 (FGF1) may hold promise as a strategy for treating Parkinson’s disease, according to a white paper released by Zhittya Genesis Medicine (ZGM). Clinical trials testing this theory are being planned.
In keeping with a burgeoning emphasis on exercise in Parkinson’s, Louisiana Tech University (LTU) has launched a dance program to help patients manage the disease. Called Dance with Parkinson’s, the program begins Feb. 5 at LTU’s Lambright Sports and Wellness Center. The goal is to get…
A medicine approved in the late 1970s to clear the respiratory tract and thin mucus can also cross the blood-brain barrier and possibly protect cells there from the damage seen in Parkinson’s disease, a small Phase 2 clinical trial has found. The study detailing these results, “Ambroxol for the Treatment…
A single dose of cannabidiol (CBD) can decrease anxiety and tremor strength in people with Parkinson’s disease during situations known to induce anxiety, such as a public speaking exercise, a study found. The results of the study, “Effects of acute cannabidiol administration on anxiety and…
A decade after its founding, the International Parkinson Disease Genomics Consortium (IPDGC) is looking back on on its first 10 years of research and outlining its goals for the future. IPDGC was started in 2009 by a small group of researchers who thought that collaborative efforts were necessary to…
By deleting a section of alpha-synuclein, a protein that forms damaging clumps in the brains of Parkinson’s disease patients, researchers were able to prevent Parkinson’s-like symptoms in fruit flies, a study reports. The study, “The Non-amyloidal Component Region of α-Synuclein Is Important for α-Synuclein Transport Within Axons,”…
Secondary parkinsonism can be caused by a cavernoma — a cluster of abnormal blood vessels — located in a brain region involved in voluntary movement control, a case report shows. The case-study, ”Nine-years follow-up of cavernoma located in basal ganglia mimicking Parkinson’s disease,” was published in the journal…
A common gut bacteria called Bacilus subtilis (B. subtilis), which aids in digestion, shows the potential to counteract the misfolded alpha-synuclein protein central to Parkinson’s disease, according to a new study. B. subtilis, a so-called “good” bacteria, slowed the buildup of this protein in the nerve cells…
Cerevel Therapeutics announced its launch of a series of Phase 3 clinical trials to evaluate its investigational therapy tavapadon, designed to improve motor function in people with Parkinson’s disease. The company will conduct three 27-week trials to evaluate tavapadon’s efficacy, safety, and tolerability in fixed doses —…
A potential oral therapy for Parkinson’s disease and amyotrophic lateral sclerosis (ALS) was seen to be safe and well-tolerated at various doses in a Phase 1 trial in healthy volunteers, its developer, Neuropore Therapies, announced. Steps are now underway to allow…
Get regular updates to your inbox.
